Cargando…

Resistance to cancer immunotherapy in metastatic renal cell carcinoma

The prognosis of metastatic clear cell renal cell carcinoma (mccRCC) has changed dramatically over the years with the emergence of immune checkpoint inhibitors (ICI) used alone, or in combination with another ICI, or with vascular endothelial growth factor receptor tyrosine kinase inhibitor. Althoug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moreira, Marco, Pobel, Cedric, Epaillard, Nicolas, Simonaggio, Audrey, Oudard, Stéphane, Vano, Yann-Alexandre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992500/ https://www.ncbi.nlm.nih.gov/pubmed/35582435 http://dx.doi.org/10.20517/cdr.2020.16

Ejemplares similares

Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
por: Simonaggio, Audrey, et al.
Publicado: (2021)

MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights
por: Simonaggio, Audrey, et al.
Publicado: (2022)

Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments
por: Procureur, Adrien, et al.
Publicado: (2021)

Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges
por: Fournier, Laure, et al.
Publicado: (2017)

Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis
por: Elaidi, Reza, et al.
Publicado: (2020)

Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies
por: Guillaume, Zoé, et al.
Publicado: (2022)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients
por: Vano, Yann-Alexandre, et al.
Publicado: (2018)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas
por: Lu, Xiaofan, et al.
Publicado: (2023)

Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
por: Guillaume, Zoé, et al.
Publicado: (2020)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC)
por: Becht, Etienne, et al.
Publicado: (2015)

Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice
por: Casuscelli, Jozefina, et al.
Publicado: (2017)

Novel immunotherapy in metastatic renal cell carcinoma
por: Cho, Yang Hyun, et al.
Publicado: (2017)

Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
por: Cohen, Roger B., et al.
Publicado: (2012)

Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma
por: Chatwal, Monica Sheila, et al.
Publicado: (2023)

Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit
por: Joseph, Adrien, et al.
Publicado: (2020)

Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
por: Tucker, Matthew D., et al.
Publicado: (2020)

Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib
por: Billemont, B, et al.
Publicado: (2008)

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
por: Vano, Yann-Alexandre, et al.
Publicado: (2021)

Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review
por: Raman, Rachna, et al.
Publicado: (2015)

Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma
por: Shao, Zhiying, et al.
Publicado: (2016)

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma
por: Rathi, Nityam, et al.
Publicado: (2019)

Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
por: Raimondi, Alessandra, et al.
Publicado: (2020)

Targeting Resident Memory T Cells for Cancer Immunotherapy
por: Blanc, Charlotte, et al.
Publicado: (2018)

The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma
por: Garje, Rohan, et al.
Publicado: (2020)

The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma
por: Su, Jiaming, et al.
Publicado: (2023)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
por: Bansal, Dhruv, et al.
Publicado: (2021)

Renal malacoplakia: Case report of a differential diagnosis for renal cell carcinoma
por: Ayllon, Jorge, et al.
Publicado: (2012)

Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma
por: Jebali, M., et al.
Publicado: (2017)

Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
por: Delanoy, Nicolas, et al.
Publicado: (2021)

Complete Pathologic Responses With Immunotherapy in Metastatic Renal Cell Carcinoma: Case Reports
por: Tucker, Matthew D., et al.
Publicado: (2020)

Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma
por: Dawsey, Scott J., et al.
Publicado: (2021)

Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches
por: Kathuria-Prakash, Nikhita, et al.
Publicado: (2021)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
por: Daban, A, et al.
Publicado: (2023)

Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy and Stereotactic Radiation Therapy or Immunotherapy Alone: A National Cancer Database Analysis
por: Piening, Alexander, et al.
Publicado: (2023)

The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
por: Raimondi, Alessandra, et al.
Publicado: (2019)

CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma
por: Tulchiner, Gennadi, et al.
Publicado: (2021)

Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma
por: Popovic, Maja, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0es6phs4iaktfnnrjrktuc8bh3